Skip to main content

ADVERTISEMENT

Michail Ignatiadis, MD, PhD

Michail Ignatiadis, MD, PhD, Jules Bordet Institute
Videos
12/07/2023
Michail Ignatiadis, MD, PhD, discusses the interim analysis of a phase 3 trial which found adding atezolizumab to adjuvant chemotherapy was very unlikely to provide benefit to patients with triple-negative breast cancer.
Michail Ignatiadis, MD, PhD, discusses the interim analysis of a phase 3 trial which found adding atezolizumab to adjuvant chemotherapy was very unlikely to provide benefit to patients with triple-negative breast cancer.
Michail Ignatiadis, MD, PhD,...
12/07/2023
Oncology